Faculty Appointments
Assistant Professor of Pediatrics
Education
M.D., Medical College of Wisconsin, Milwaukee, WisconsinPh.D., Medical College of Wisconsin, Milwaukee, WisconsinB.S., Michigan State University, East Lansing, Michigan
Research Description
Dr. Stephanie Rolsma is an assistant professor in the Division of Pediatric Infectious Diseases at Monroe Carell Jr. Children’s Hospital at Vanderbilt.
Dr. Rolsma has experience in microbiology, vaccine development, and clinical research and her current research focuses on therapeutics and interventions in critically ill patients and clinical trials. Her primary research focuses on evaluating the utility of therapeutic drug monitoring of beta-lactam antibiotics in pediatric and adult patients, including cystic fibrosis patients and patients receiving intensive critical care. She also serves as a co-investigator in studies conducted through the NIH-funded Vanderbilt Vaccine and Treatment Evaluation Unit (VTEU), including Moderna and Janssen Phase 3 SARS-CoV-2 vaccine trials in adults, a Moderna Phase 2/3 SARS-CoV-2 vaccine trial in children, a Moderna Phase 1 SARS-CoV-2 variant vaccine trial in adults, a study of infant immune responses to RSV, and an intranasal influenza vaccine in pediatric patients. As a co-investigator for the CDC-funded Clinical Immunization Safety Assessment Network she works to address safety issues and clinical adverse events following vaccinations.
Dr. Rolsma received her B.S. in Microbiology from Michigan State University. She was awarded a Ph.D. in Microbiology and Molecular Genetics and M.D. from the Medical College of Wisconsin, where she was a part of the Medical Scientist Training Program. She completed a residency in pediatrics and a fellowship in pediatric infectious diseases at Monroe Carell Jr. Children’s Hospital at Vanderbilt.
Dr. Rolsma has experience in microbiology, vaccine development, and clinical research and her current research focuses on therapeutics and interventions in critically ill patients and clinical trials. Her primary research focuses on evaluating the utility of therapeutic drug monitoring of beta-lactam antibiotics in pediatric and adult patients, including cystic fibrosis patients and patients receiving intensive critical care. She also serves as a co-investigator in studies conducted through the NIH-funded Vanderbilt Vaccine and Treatment Evaluation Unit (VTEU), including Moderna and Janssen Phase 3 SARS-CoV-2 vaccine trials in adults, a Moderna Phase 2/3 SARS-CoV-2 vaccine trial in children, a Moderna Phase 1 SARS-CoV-2 variant vaccine trial in adults, a study of infant immune responses to RSV, and an intranasal influenza vaccine in pediatric patients. As a co-investigator for the CDC-funded Clinical Immunization Safety Assessment Network she works to address safety issues and clinical adverse events following vaccinations.
Dr. Rolsma received her B.S. in Microbiology from Michigan State University. She was awarded a Ph.D. in Microbiology and Molecular Genetics and M.D. from the Medical College of Wisconsin, where she was a part of the Medical Scientist Training Program. She completed a residency in pediatrics and a fellowship in pediatric infectious diseases at Monroe Carell Jr. Children’s Hospital at Vanderbilt.
Research Keywords
vaccine, vaccine safety, antibiotic pharmacokinetics/pharmacodynamics, therapeutic drug monitoring
Publications
An G, Creech CB, Wu N, Nation RL, Gu K, Nalbant D, Jimenez-Truque N, Fissell W, Patel PC, Fishbane N, Watanabe A, Rolsma S, Kirkpatrick CMJ, Landersdorfer CB, Winokur P. Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients. J Antimicrob Chemother. 2023 Jun 6/1/2023; 78(6): 1460-70. PMID: 37071586, PMCID: PMC10474939, PII: 7127727, DOI: 10.1093/jac/dkad106, ISSN: 1460-2091.
Rolsma SL, Yoder SM, Nargi RS, Brady E, Jimenez-Truque N, Thomsen I, Kontos M, Carnahan RH, Sutton RE, Armstrong E, Dally L, Crowe JE, Edwards KM, Creech CB. Development of a Kinetic ELISA and Reactive B Cell Frequency Assay to Detect Respiratory Syncytial Virus Pre-Fusion F Protein-Specific Immune Responses in Infants. J Pediatric Infect Dis Soc. 2023 May 5/31/2023; 12(5): 298-305. PMID: 37029694, PMCID: PMC10231354, PII: 7111176, DOI: 10.1093/jpids/piad019, ISSN: 2048-7207.
Follmann D, Janes HE, Chu E, Jayashankar L, Petropoulos CJ, Serebryannyy L, Carroll R, Jean-Baptiste N, Narpala S, Lin BC, McDermott A, Novak RM, Graciaa DS, Rolsma S, Magaret CA, Doria-Rose N, Corey L, Neuzil KM, Pajon R, Miller JM, Donis RO, Koup RA, Baden LR, El Sahly HM. Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. Open Forum Infect Dis. 2023 Mar; 10(3): ofad069. PMID: 36895286, PMCID: PMC9991588, PII: ofad069, DOI: 10.1093/ofid/ofad069, ISSN: 2328-8957.
Searns JB, Rice JD, Bertin KB, Birkholz M, Barganier LB, Creech CB, Downes KJ, Hubbell BB, Kronman MP, Rolsma SL, Sydney GI, O'Leary ST, Parker SK, Dominguez SR. Using Administrative Billing Codes to Identify Acute Musculoskeletal Infections in Children. Hosp Pediatr. 2023 Feb 2/1/2023; 13(2): 182-95. PMID: 36601701, PII: 190433, DOI: 10.1542/hpeds.2022-006821, ISSN: 2154-1671.
An G, Creech CB, Wu N, Nation RL, Gu K, Nalbant D, Jimenez-Truque N, Fissell W, Rolsma S, Patel PC, Watanabe A, Fishbane N, Kirkpatrick CMJ, Landersdorfer CB, Winokur P. Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis. Antimicrob Agents Chemother [print-electronic]. 2023 Jan 1/24/2023; 67(1): e0131222. PMID: 36622154, PMCID: PMC9872596, DOI: 10.1128/aac.01312-22, ISSN: 1098-6596.
Rolsma SL, Rankin DA, Haddadin Z, Hamdan L, Rahman HK, Faouri S, Shehabi A, Williams JV, Khuri-Bulos N, Halasa NB. Assessing the epidemiology and seasonality of influenza among children under two hospitalized in Amman, Jordan, 2010-2013. Influenza Other Respir Viruses [print-electronic]. 2021 Mar; 15(2): 284-92. PMID: 33175456, PMCID: PMC7902256, DOI: 10.1111/irv.12813, ISSN: 1750-2659.
Rolsma SL, Frank DW. In vitro assays to monitor the activity of Pseudomonas aeruginosa Type III secreted proteins. Methods Mol Biol. 2014; 1149: 171-84. PMID: 24818904, PMCID: PMC5860653, DOI: 10.1007/978-1-4939-0473-0_14, ISSN: 1940-6029.
Rolsma SL, Yoder SM, Nargi RS, Brady E, Jimenez-Truque N, Thomsen I, Kontos M, Carnahan RH, Sutton RE, Armstrong E, Dally L, Crowe JE, Edwards KM, Creech CB. Development of a Kinetic ELISA and Reactive B Cell Frequency Assay to Detect Respiratory Syncytial Virus Pre-Fusion F Protein-Specific Immune Responses in Infants. J Pediatric Infect Dis Soc. 2023 May 5/31/2023; 12(5): 298-305. PMID: 37029694, PMCID: PMC10231354, PII: 7111176, DOI: 10.1093/jpids/piad019, ISSN: 2048-7207.
Follmann D, Janes HE, Chu E, Jayashankar L, Petropoulos CJ, Serebryannyy L, Carroll R, Jean-Baptiste N, Narpala S, Lin BC, McDermott A, Novak RM, Graciaa DS, Rolsma S, Magaret CA, Doria-Rose N, Corey L, Neuzil KM, Pajon R, Miller JM, Donis RO, Koup RA, Baden LR, El Sahly HM. Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. Open Forum Infect Dis. 2023 Mar; 10(3): ofad069. PMID: 36895286, PMCID: PMC9991588, PII: ofad069, DOI: 10.1093/ofid/ofad069, ISSN: 2328-8957.
Searns JB, Rice JD, Bertin KB, Birkholz M, Barganier LB, Creech CB, Downes KJ, Hubbell BB, Kronman MP, Rolsma SL, Sydney GI, O'Leary ST, Parker SK, Dominguez SR. Using Administrative Billing Codes to Identify Acute Musculoskeletal Infections in Children. Hosp Pediatr. 2023 Feb 2/1/2023; 13(2): 182-95. PMID: 36601701, PII: 190433, DOI: 10.1542/hpeds.2022-006821, ISSN: 2154-1671.
An G, Creech CB, Wu N, Nation RL, Gu K, Nalbant D, Jimenez-Truque N, Fissell W, Rolsma S, Patel PC, Watanabe A, Fishbane N, Kirkpatrick CMJ, Landersdorfer CB, Winokur P. Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis. Antimicrob Agents Chemother [print-electronic]. 2023 Jan 1/24/2023; 67(1): e0131222. PMID: 36622154, PMCID: PMC9872596, DOI: 10.1128/aac.01312-22, ISSN: 1098-6596.
Rolsma SL, Rankin DA, Haddadin Z, Hamdan L, Rahman HK, Faouri S, Shehabi A, Williams JV, Khuri-Bulos N, Halasa NB. Assessing the epidemiology and seasonality of influenza among children under two hospitalized in Amman, Jordan, 2010-2013. Influenza Other Respir Viruses [print-electronic]. 2021 Mar; 15(2): 284-92. PMID: 33175456, PMCID: PMC7902256, DOI: 10.1111/irv.12813, ISSN: 1750-2659.
Rolsma SL, Frank DW. In vitro assays to monitor the activity of Pseudomonas aeruginosa Type III secreted proteins. Methods Mol Biol. 2014; 1149: 171-84. PMID: 24818904, PMCID: PMC5860653, DOI: 10.1007/978-1-4939-0473-0_14, ISSN: 1940-6029.